Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: A comparison of 1 and 6 weeks of treatment

Journal of Glaucoma

Volumn 19, Issue 6, 2010, Pages 356-364

  Johnson, Thomas V ^a,b   Fan, Shan ^a   Zhan, Guilin ^a   Camras, Carl B ^a   Toris, Carol B ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

aqueous flow; aqueous humor dynamics; intraocular pressure; latanoprost; outflow facility; timolol

Indexed keywords

LATANOPROST; TIMOLOL; ANTIHYPERTENSIVE AGENT; PROSTAGLANDIN F;

ADULT; AQUEOUS HUMOR FLOW; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA THICKNESS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FLUOROPHOTOMETRY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OCULOPLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCLERA; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS PRESSURE; AQUEOUS HUMOR; DRUG EFFECTS; GONIOSCOPY; METABOLISM; MIDDLE AGED; OCULAR HYPERTENSION; SECRETION (PROCESS); TIME; UVEA;

ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FLUOROPHOTOMETRY; GONIOSCOPY; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; SCLERA; TIME FACTORS; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME; UVEA;

EID: 77956016049     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181d12dd8     Document Type: Article

References (48)

1. Toris CB, Koepsell SA, Yablonski ME, et al. Aqueous humor dynamics in ocular hypertensive patients. J Glaucoma. 2002; 11:253-258.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90:262-267.
3. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103:138-147.
4. Mastropasqua L, Carpineto P, Ciancaglini M, et al. A 12- month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology. 1999;106:550-555.
5. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10:95-104.
6. Hedman K, Alm A, Gross RL. Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J Glaucoma. 2003;12: 463-465.
7. Varma R, Hwang LJ, Grunden JW, et al. Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range. Am J Ophthalmol. 2009;148:221-226.
8. Camras CB, Hedman K. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma. 2003;12:466-469.
9. Yablonski ME, Zimmerman TJ, Waltman SR, et al. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 1978;27:135-142.
10. Wayman L, Larsson LI, Maus T, et al. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:1368-1371.
11. Larsson LI. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination. Arch Ophthalmol. 2001;119:492-495.
12. Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol. 1982;93:232-237.
13. Ziai N, Dolan JW, Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351-1358.
14. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-1304.
15. Tabet R, Stewart WC, Feldman R, et al. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol. 2008;53 (Suppl 1):S85-S92.
16. Lim KS, Nau CB, O'Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008;115:790-795.
17. Poyer JF, Millar C, Kaufman PL. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 1995;36:2461-2465.
18. Alphen GW, Wilhelm PB, Elsenfeld PW. The effect of prostaglandins on the isolated internal muscles of the mammalian eye, including man. Doc Ophthalmol. 1977;42:397-415.
19. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179-191.
20. Sagara T, Gaton DD, Lindsey JD, et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999; 117:794-801.
21. Gaton DD, Sagara T, Lindsey JD, et al. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol. 2001;119:1165-1170.
22. Anthony TL, Lindsey JD, Weinreb RN. Latanoprost's effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells. Invest Ophthalmol Vis Sci. 2002;43:3705-3711.
23. Weinreb RN, Lindsey JD. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci. 2002;43:716-722.
24. Weinreb RN, Lindsey JD, Marchenko G, et al. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest Ophthalmol Vis Sci. 2004;45:4368-4377.
25. Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38: 2772-2780.
26. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Survey Ophthalmology. 2008;53 (Suppl 1):S107-120.
27. Steinert RF, Thomas JV, Boger WP, III. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol. 1981;99:100-103.
28. Brubaker RF, Nagataki S, Bourne WM. Effect of chronically administered timolol on aqueous humor flow in patients with glaucoma. Ophthalmology. 1982;89:280-283.
29. Bengtsson B, Heijl A. Lack of long-term drift in timolol's effectiveness in patients with ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:2839-2842.
30. Stamper RL, Lieberman MF, Drake MV. Becker-Schaffer's diagnosis and therapy of the glaucomas. St. Louis, MO: Mosby; 1999:101-113.
31. Schenker HI, Yablonski ME, Podos SM, et al. Fluorophotometric study of epinephrine and timolol in human subjects. Arch Ophthalmol. 1981;99:1212-1216.
32. Hayashi M, Yablonski ME, Mindel JS. Methods for assessing the effects of pharmacologic agents on aqueous humor dynamics. In: Tasman W, Jaeger EA, eds. Duane's foundations of clinical ophthalmology. Philadelphia: Lippincott; 1993:1-9.
33. Yablonski ME, Cook DJ, Gray J. A fluorophotometric study of the effect of argon laser trabeculoplasty on aqueous humor dynamics. Am J Ophthalmol. 1985;99:579-582.
34. Hayashi M, Yablonski ME, Novack GD. Trabecular outflow facility determined by fluorophotometry in human subjects. Exp Eye Res. 1989;48:621-625.
35. Toris CB, Zhan G, Fan S, et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma. 2007;16:189-195.
36. Wayman LL, Larsson LI, Maus TL, et al. Additive effect of dorzolamide on aqueous humor flow in patients receiving longterm treatment with timolol. Arch Ophthalmol. 1998;116: 1438-1440.
37. Frampton JE, Perry CM. Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006; 23:977-995.
38. O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol. 2002;133:836-837.
39. Maruyama K, Shirato S. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. J Glaucoma. 2006;15: 341-345.
40. Kimal Arici M, Topalkara A, Guler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol. 1998;22:37-42.
41. Berson FG, Epstein DL. Separate and combined effects of timolol maleate and acetazolamide in open-angle glaucoma. Am J Ophthalmol. 1981;92:788-791.
42. Kanno M, Araie M, Koibuchi H, et al. Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans. Br J Ophthalmol. 2000;84: 293-299.
43. Sponsel WE, Mensah J, Kiel JW, et al. Effects of latanoprost and timolol-XE on hydrodynamics in the normal eye. Am J Ophthalmol. 2000;130:151-159.
44. Crawford KS, Kaufman PL. Dose-related effects of prostaglandin F2 alpha isopropylester on intraocular pressure, refraction, and pupil diameter in monkeys. Invest Ophthalmol Vis Sci. 1991;32:510-519.
45. Johnson TV, Fan S, Camras CB, et al. Aqueous humor dynamics in exfoliation syndrome. Arch Ophthalmol. 2008;126:914-920.
46. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128:8-14.
47. Toris CB, Yablonski ME, Wang YL, et al. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol. 1999;127: 407-412.
48. Kiland JA, Gabelt BT, Kaufman PL. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res. 2004;78:639-651.